Email this article -Blokatory - dokazano!
- Authors: Silina EG1, Aleksanyan LA1
-
Affiliations:
- Issue: Vol 8, No 3 (2011)
- Pages: 25-29
- Section: Articles
- URL: https://journals.eco-vector.com/2075-082X/article/view/33109
- DOI: https://doi.org/10.26442/SG33109
- ID: 33109
Cite item
Full Text
Abstract
References
- Kannel W, Kannel C, Paffenbarger RS Jr, Cupples LA. Heart rate and cardiovascular mortality: the Framingham Study. Am Heart J 1987; 113: 1489-94.
- Kjekshus J, Gullestad L. Heart rate as a therapeutic target in heart failure. Eur Heart J 1999; 1: H64-9.
- Messerli FH, Grossman E, Goldbourt U. Are beta-blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review JAMA 1998; 279: 1903-7.
- Aronow WS, Ahn C. Incidence of new coronary events in older persons with prior myocardial infarction and systemic hypertension treated with beta-blockers, angiotensin-converting enzyme inhibitors, diuretics, calcium antagonists, and alpha blockers. Am J Cardiol 2002; 89: 1207-9.
- Kjekshus JK. Importance of heart rate in determining beta-blocker efficacy in acute and long-term acute myocardial infarction intervention trials. Am J Cardiol 1986; 57: 43F-9F.
- Cucherat M. Quantitative relationship between resting heart rate reduction and magnitude of clinical benefits in post-myocardial infarction: a meta-regression of randomized clinical trials. Eur Heart J 2007; 28: 3012-19.
- Smith SC Jr, Allen J, Blair SN et al. ACC/AHA guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung and Blood Institute. Circulation 2006; 113: 2363-72.
- Smith SC Jr, Blair SN, Bonow RO et al. AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update. A statement for healthcare professionals from the American Heart Association and the American College of Cardiology. J Am Coll Cardiol 2001; 38: 1581-3.
- Chobanian AV, Bakris GL, Black HR et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC 7 Report. JAMA 2003; 289: 2560-72.
- Mancia G, Laurent S, Agabiti-Rosei E et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009; 27: 2121-58.
- Goch A, Banach M, Mikhailidis DP et al. Endothelial dysfunction in patients with noncomplicated and complicated hypertension. Clin Exp Hypertens 2009; 31: 20-30.
- Navneet S Mechanisms of the beneficial effects of beta-adrenoceptor antagonists in congestive heart failure. Exp Clin Cardiol 2010; 15 (4): e86-95.
- Marazzi G, Iellamo F, Volterrani M, Caminiti G et al. Comparison of effectiveness of carvedilol versus bisoprolol for prevention of postdischarge atrial fibrillation after coronary artery bypass grafting in patients with heart failure. Am J Cardiol 2011; 107 (2): 215-9. Epub 2010 Dec 2.
- Wang B, Song WH, Liu GZ. Multi-center Cooperation Group of Bisoprolol. The effect long-term administration of a selective beta1 blocker bisoprolol on glucose metabolism in patients with essential hypertensive and type 2 diabetes mellitus. Zhonghua Nei Ke Za Zhi 2005; 44 (7): 503-5.
- Haas SJ, Vos T, Gilbert RE, Krum H. Are beta-blockers as efficacious in patients with diabetes mellitus as in patients without diabetes mellitus who have chronic heart failure? A meta-analysis of large-scale clinical trials. Am Heart J 2003; 146 (5): 848-53.
- Kokkinos P, Chrysohoou C, Panagiotakos D et al. Beta-blockade mitigates exercise blood pressure in hypertensive male patients. J Am Coll Cardiol 2006; 47: 794.
- Lopez-Sendon J, Swedberg K, McMurray J et al. Expert consensus document on beta-adrenergic receptor blockers. Eur Heart J 2004; 25: 1341-62.
- Manrique C, Giles TD, Ferdinand KC et al. Realities of newer beta-blockers for the management of hypertension. J Clin Hypertens 2009; 11: 369-75.
- UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38, 39. Brit Med J 1998; 317: 703-9.
Supplementary files
